Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

IR Contact

The principal task of Immunovia’s Investor Relations is to provide investors and the capital market with accurate, relevant and timely information that facilitates an understanding of the operations of Immunovia AB.

Contact Investor Relations for details:

Karin Almqvist Liwendahl

Chief Financial Officer


Phone: +46 709 11 56 08